New schizophrenia drug shows promise in early trial
Disease control
Completed
This study tested a new drug called LB-102 in 359 adults with acute schizophrenia. Participants received either LB-102 or a placebo for 28 days. The goal was to see if LB-102 reduces symptoms like hallucinations and confusion better than a placebo. The trial is now complete, and …
Phase: PHASE2 • Sponsor: LB Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC